PDB rendering based on 1v7m.
|Symbols||; MGDF; MKCSF; ML; MPLLG; THCYT1; TPO|
|External IDs||ChEMBL: GeneCards:|
|RNA expression pattern|
Thrombopoietin is a glycoprotein hormone produced by the liver and kidney which regulates the production of platelets. It stimulates the production and differentiation of megakaryocytes, the bone marrow cells that bud off large numbers of platelets.
Megakaryocytopoiesis is the cellular development process that leads to platelet production. The protein encoded by this gene is a humoral growth factor necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene.
The thrombopoietin gene is located on the long arm of chromosome 3 (q26.3-27). Abnormalities in this gene occur in some hereditary forms of thrombocytosis (high platelet count) and in some cases of leukemia. The first 155 amino acids of the protein share homology with erythropoietin.
Function and regulation
Thrombopoietin is produced in the liver by both parenchymal cells and sinusoidal endothelial cells, in the kidney by proximal convoluted tubule cells. Small amounts are also made by striated muscle and bone marrow stromal cells. In the liver, its production is augmented by interleukin 6 (IL-6). However, the liver and the bone marrow stromal cells are the primary sites of thrombopoietin production.
Its negative feedback is different from that of most hormones in endocrinology: The effector regulates the hormone directly. Thrombopoietin is bound to the surface of platelets by the mpl receptor (CD 110) and destroyed, thereby reducing megakaryocyte exposure to the hormone. Therefore, the rising and dropping platelet concentrations regulate the thrombopoietin levels. Low platelets lead a higher degree of thrombopoietin exposure to the undifferentiated bone marrow cells, leading to differentiation into megakaryocytes and further maturation of these cells. On the other hand, high platelet concentrations lead to less availability of thrombopoietin to megakaryocytes.
Despite numerous trials, thrombopoietin has not been found to be useful therapeutically. Theoretical uses include the procurement of platelets for donation, recovery of platelet counts after myelosuppressive chemotherapy.
Trials of a modified recombinant form, megakaryocyte growth and differentiation factor (MGDF), were stopped when healthy volunteers developed autoantibodies to endogenous thrombopoietin and then developed thrombocytopenia. Romiplostim and Eltrombopag, structurally different compounds that stimulate the same pathway, are used instead.
Thrombopoietin was cloned by five independent groups in 1994. Before its identification, its function has been hypothesized for as much as 30 years as being linked to the cell surface receptor c-Mpl, and in older publications thrombopoietin is described as c-Mpl ligand (the agent that binds to the c-Mpl molecule). Thrombopoietin is one of the Class I hematopoietic cytokines.
- Kaushansky K (2006). "Lineage-specific hematopoietic growth factors". N. Engl. J. Med. 354 (19): 2034–45. doi:10.1056/NEJMra052706. PMID 16687716.
- "Entrez Gene: THPO thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor)".
- Online 'Mendelian Inheritance in Man' (OMIM) 600044
- Kuter DJ, Goodnough LT, Romo J, et al. (2001). "Thrombopoietin therapy increases platelet yields in healthy platelet donors". Blood 98 (5): 1339–45. doi:10.1182/blood.V98.5.1339. PMID 11520780.
- Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ (December 2001). "Thrombocytopenia caused by the development of antibodies to thrombopoietin". Blood 98 (12): 3241–8. doi:10.1182/blood.V98.12.3241. PMID 11719360.
- Imbach P, Crowther M (August 2011). "Thrombopoietin-receptor agonists for primary immune thrombocytopenia". N. Engl. J. Med. 365 (8): 734–41. doi:10.1056/NEJMct1014202. PMID 21864167.
- Nakamura T, Miyakawa Y, Miyamura A, et al. (2006). "A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis". Blood 107 (11): 4300–7. doi:10.1182/blood-2005-11-4433. PMID 16484588.
- Jenkins JM, Williams D, Deng Y, et al. (2007). "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist". Blood 109 (11): 4739–41. doi:10.1182/blood-2006-11-057968. PMID 17327409.
- Hitchcock IS, Kaushansky K (2014). "Thrombopoietin from beginning to end". Br. J. Haematol. 165 (2): 259–68. doi:10.1111/bjh.12772. PMID 24499199.
- Wörmann B (2013). "Clinical indications for thrombopoietin and thrombopoietin-receptor agonists". Transfus Med Hemother 40 (5): 319–25. doi:10.1159/000355006. PMC 3822275. PMID 24273485.
- Kuter DJ (2013). "The biology of thrombopoietin and thrombopoietin receptor agonists". Int. J. Hematol. 98 (1): 10–23. doi:10.1007/s12185-013-1382-0. PMID 23821332.
- Lupia E, Goffi A, Bosco O, Montrucchio G (2012). "Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseases". Mediators Inflamm. 2012: 390892. doi:10.1155/2012/390892. PMC 3337636. PMID 22577249.
- Liebman HA, Pullarkat V (2011). "Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics". Hematology Am Soc Hematol Educ Program 2011: 384–90. doi:10.1182/asheducation-2011.1.384. PMID 22160062.